# LDE225 and Paclitaxel in Solid Tumors

> **NCT01954355** · PHASE1 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor
- Ovarian Cancer

## Interventions

- **DRUG:** LDE225
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01954355
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-10
- **Final completion:** 2016-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01954355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01954355, "LDE225 and Paclitaxel in Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01954355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*